Sign In   |   Register

New European Atherosclerosis Society Consensus Panel statement:

‘State of the Art’ on low-density lipoproteins and cardiovascular disease

February 13, 2020, Gothenburg, Sweden – Low-density lipoproteins (LDL) are the key driver of atherosclerosis, the process that underpins cardiovascular complications such as heart attack and stroke. Clinicians dealing with patients with cardiovascular disease have, however, lacked an up-to-date overview of the underlying pathophysiological mechanisms. The European Atherosclerosis Society (EAS) Consensus Panel has addressed this in a new statement, published today in The European Heart Journal.  This follow-up to a previous EAS Consensus Panel statement on clinical data for the causal role of LDL in cardiovascular disease,1 represents a unique, valuable resource for clinicians.

Consensus Panel Co-Chair, Professor M. John Chapman, National Institute for Health and Medical Research (INSERM), Sorbonne University, and Pitie-Salpetriere University Hospital, Paris, France explained the need for this new statement. ‘Our understanding of the causal role of LDL in atherosclerotic cardiovascular disease has progressed substantially in recent years. As a consequence, there is the need for an integrated narrative focussing on the complex pathophysiology of this chronic, insidious disease at the molecular, cellular and tissue levels. This rationale provided the impetus for this new consensus statement from the EAS Consensus Panel.’


To the Consensus paper >>

February 2020, Featured Commentary

The 2019 ESC/EAS guidelines recommend lower LDL cholesterol levels to optimise global cardiovascular risk reduction. A key practical deterrent, however, is adherence. This month’s commentary discusses new evidence for early intervention to optimise population health, together with novel approaches that may offer solutions to the issue of poor adherence.

Targeting LDL cholesterol: early treatment is key to population health

Lower LDL cholesterol is better’ is a key premise of the 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS Guidelines for Dyslipidaemia).1 Low-density lipoprotein(LDL) is indisputably causal for atherosclerotic cardiovascular disease (ASCVD),2 and clinical data show no evidence of a threshold for clinical benefit from LDL-lowering.3,4 Indeed, it should be borne in mind that the LDL cholesterol goals in the ESC/EAS Guidelines are the maximum recommended levels for each global risk category, and that clinicians should aim for values below these wherever possible.

Given that atherosclerosis is a chronic inflammatory disease, it would make good clinical and economic sense to intervene against LDL cholesterol earlier, before the advent of subclinical disease. There has, however, been uncertainty regarding the clinical benefit derived at different baseline LDL cholesterol levels.  This question (amongst others) was the focus of a recent meta-analysis.5


Member sign in

Our community advances and exchanges knowledge about atherosclerosis and related disease. Our members’ subscription fees help to support the Society’s Publication, Education and Outreach programmes, which in turn benefit our members through networking and scientific development.

We're pleased to share an update on the progress we have made in the Society’s activities during 2019. Read more in our "Review of the year" >>

All EAS activities and initiatives are conceived, planned and carried out by dedicated and driven individuals, who devote much time, energy and enthusiasm to the life of the Society. Thank you for your contribution to our community.

Calendar more

Advanced Course in Rare Lipid Disease - Berlin

Advanced Course in Rare Lipid Disease - St Petersburg

25/03/2020 » 29/03/2020
4th Dubrovnik Lipidology School

EAS Academy
EAS Journal
Become an EAS Member
Membership Software Powered by YourMembership  ::  Legal
This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.